INTRODUCTION
The development of resistance to the cytotoxicity of carcinogens is a frequent feature of carcinogenesis including aflatoxin Bi (AFB,)-induced hepatocarcinogenesis in the rat (Judah et al., 1977) . It has been hypothesized that it represents an important step in multistage carcinogenesis, in that it permits DNA replication and cell proliferation in the presence of a carcinogen which normally inhibits these processes (Farber et al., 1975) . Possible biochemical mechanisms include loss of xenobiotic activating capacity (Farber et al., 1976) and increased detoxification (Neal et al., 1981a) . A glutathione S-transferase (GST) isoenzyme Alpha-class subunit Yc2 is expressed in AFB1-induced pre-neoplastic rat liver as heterodimers with subunits Yal or Ycl. These Yc2-containing GSTs have high AFB1-conjugating activity, and probably play a major role in resistance in preneoplastic and neoplastic rat liver (Hayes et al., 199 la) . The Yc2 subunit is expressed in the livers of rats after administration of the anti-oxidant ethoxyquin, which also induces resistance to AFB1 (Hayes et al., 199 la) , and it also shares extensive sequence similarity with the constitutively expressed Yc GST-isoenzyme subunit (Hayes et al., 1991b (Hayes et al., , 1992 Buetler and Eaton, 1992) in the AFB1-resistant mouse.
During previous studies we had noted in incubations using cytosolic fractions from pre-neoplastic and ethoxyquin-treated livers, in addition to increased AFB1-GSH formation, the capacity to form an apparently previously unreported metabolite. The formation of this metabolite was not evident in incubations using cytosolic fractions from control rats. We now describe the isolation and characterization of this metabolite as AFB1-dialcohol. It is formed from AFB1-dihydrodiol (AFB1-dhd) in the dialdehyde configuration, by a novel AFB1-dhd aldehyde reductase (AFB1-AR). AFB1-dhd is capable of binding to protein via Schiff-base formation and it has been suggested that this reaction is involved in cytotoxicity (Neal et al., 198 lb the newly identified AFB1-AR might have significant detoxifying potential, a role which would be consistent with its expression in pre-neoplastic liver or following the administration of the antioxidant, ethoxyquin.
MATERIALS AND METHODS Animals
Male Fischer F344 rats bred on site at the MRC Toxicology Unit, were fed a basic diet of powdered MRC 41 B with arachis oil (20 ml/kg of diet), or the basic diet plus ethoxyquin (5 ml/kg of diet) or the basic diet plus AFB1 (2 mg/kg of diet) with arachis oil (20 ml/kg of diet) as the vehicle. Experimental feedings were commenced at 150 g body wt. in the case of the ethoxyquin administration and continued for 5 days. Control and experimental groups of three rats were then killed and the livers rapidly frozen in liquid N2. Other groups of rats were fed the AFB1-containing diet for approx. 6 months from weanling stage and were killed at approx. 1 year of age. Livers were removed and rapidly frozen. Small portions of the livers were removed before freezing the tissue, fixed in cold acetone and the presence of altered cell foci and nodules in the rats fed the AFB1 diet was confirmed by histological examination and histochemistry using y-glutamyltransferase as a marker (Manson and Neal, 1987) . Hepatic microsomal suspensions were prepared from quail liver in 150 mM KCI as described previously Enzyme fractionation (a) GSH-affinity gel Cytosolic fractions (supernatants from 100000 g centrifugation for 1 h), prepared from frozen livers in 20 mM Tris/HCl (pH 7.8) containing 100 mM NaCl were passed through a column of a glutathione-Sepharose 6B affinity matrix essentially as described previously (Hayes, 1986) . The adsorbed GST activity, after washing the column with the Tris/HCl homogenizing solution, was eluted with a solution of 50 mM GSH in 200 mM Tris/HCl (pH 9.0) and subsequently dialysed against two changes, each of 2 litres, of 20 mM Tris/HCl (pH 7.8) (Hayes, 1986) .
(b) Ion-exchange hydroxyapatite chromatography and f.p.l.c. Liver post-mitochondrial supernatants (10000 g, 30 min) prepared in 20 mM Tris/HCl (pH 7.5) were fractionated sequentially on DEAE-cellulose, CM-cellulose, hydroxyapatite and Protein-PAK Glass SP-8HR columns using essentially the conditions used previously to fractionate GST (Hayes et al., 199 lb) . Fractions were monitored for the capacity to catalyse the formation of the novel metabolite of AFB1 throughout the successive column separations. Electrophoresis SDS/PAGE was performed by the method of Laemmli (1970) . The resolving gels employed 12% (w/v) polyacrylamide which contained 0.32% NN-methylenebisacrylamide as described previously (Hayes and Mantle, 1986 ).
Aldehyde reductase assay
Aldehyde reductase activity was determined at 30°C by a modification of the method of Ryle and Tipton (1981) using 73 ,uM 4-nitrobenzaldehyde as a model substrate and 0.075 mM NADPH in 100 mM sodium phosphate buffer (pH 7.0), monitoring the reaction by AA340nm' Protein assays These were carried out by the dye-binding method of Bradford (1976) .
Enzyme Incubatlon and h.p.l.c. procedures (a) Analytical Incubations in which activation of AFB1 to form AFB1-8,9-epoxide was catalysed by quail microsomes, thus providing the substrate for secondary metabolism by cytosols or fractions of cytosols, were essentially as described previously for assay of AFB1-GST activity (Hayes et al., 1991a) , GSH being omitted from the incubation mixtures where indicated. H.p.l.c. sample preparations and separations of metabolites following incubations were also essentially as described previously (Hayes et al., 1991b ). H.p.l.c. eluants were monitored using u.v. absorption (365 nm) and fluorescence (365 nm band-pass excitation/405 nm long-pass emission). 3H binding to protein was assayed by dissolving the methanol-insoluble pellets (obtained by centrifuging the incubation media after addition of methanol) in NaOH, followed by scintillation-counting in acidified Monofluor (National Diagnostics, Aylesbury, Bucks., U.K.).
In some incubations AFB1-8,9-epoxide, generated in situ by quail microsomes, was replaced by AFB1-dhd, which was generated in incubation mixtures containing AFB1 (1.1 ,umol), quail liver microsomes (equivalent to 3.2 g of liver), potassium phosphate buffer (2 mmol, pH 7.4), MgCl2 (127 , umol) , NADP+ (1.1 ,umol), glucose 6-phosphate (157 ,umol), glucose-6-phosphate dehydrogenase (8 units) and distilled water to a total volume of 24.4 ml, and incubated under 2 at 37°C for 2 h. This incubation protocol ensured a virtually complete metabolism of the AFB1 and so avoided its carry-over into the second incubation. The post-incubation reaction mixture was clarified by centrifugation (100000 g, 60 min) and 2 ml aliquots of the supernatant were loaded on to an activated C18 Sep-Pak cartridge (Millipore, Watford, Herts., U.K.), washed (2 x 2 ml of water) without application of positive pressure to avoid elution of weakly retained AFB1-dhd, which was then eluted with 2 ml ofmethanol/ water (1:1, v/v) followed by 2 ml of methanol. The combined eluates were dried in a Savant Vacuum Concentrator (IEC Ltd., Dunstable, Beds., U.K.). The residue was dissolved in potassium phosphate buffer (0.8 M, pH 7.4), analysed by h.p.l.c. to confirm > 95 % purity of AFB1-dhd, and stored at -20 'C. Samples were routinely used within one day of preparation because significant degradation occurred on storage.
(b) Preparative Samples of the novel metabolite were prepared for analysis by n.m.r. spectroscopy and m.s. using the incubation system described in the Materials and methods section, incorporating purified AFB1-AR [i.e. obtained from the hydroxyapatite pool; see Enzyme fractionation procedure (b)]. Quail microsomes equivalent to 375 mg of liver in a total volume of 7.32 ml were incubated with appropriate cofactors for 20 min. The reactions were terminated by the addition of 4 vol. of ice-cold methanol followed by centrifugation. The extracts were evaporated to dryness in a Savant Vacuum Concentrator and redissolved in 1.5 ml of 5 % (v/v) methanol/0.05 % formic acid (Solvent A).
Aliquots (3 x 100 #l) of the solution were used for on-column concentration using the h.p.l.c. system described previously (Hayes et al., 1991b ) and a flow rate of 1 ml/min of Solvent A. The on-column concentrated metabolite was subsequently eluted by initiating a linear gradient from 100 % of Solvent A to 50 % (v/v) methanol (Solvent B) (7 min). The novel metabolite eluted with a retention time (tR) of 6 min, the appropriate fractions monitored by u.v. absorption were collected. This procedure was repeated five times, and the combined metabolite-containing fractions were evaporated to dryness in a Savant Vacuum Concentrator and used subsequently in the n.m.r. and m.s. studies.
N.m.r. analyses Spectra were obtained, using a Bruker AM 500 spectrometer operating at a proton frequency of 500 MHz at 298 k and at pH 7.4. Two-dimensional dual-quantum-field correlated spectroscopy (DQF-COSY) spectra were acquired using a data matrix Figure Id , peak a) not observed in incubations using control cytosols. Although most of the results given in this paper relate to experiments using fractions isolated from ethoxyquin-treated liver, similar studies using cytosols from pre-neoplastic liver have revealed the capacity to form an identical metabolite. Subsequent fractionation of cytosols by GSH-Sepharose 6B affinity chromatography [enzyme fractionation (a) in the Materials and methods section] into retained and non-retained subfractions demonstrated that production of the novel metabolite was associated entirely with the non-retained, GST-depleted, fraction (Figure le) . The Tris-AFB1-dhd (peak b, Figure 1 ) is produced by the Schiff-base reaction between AFB1-dhd in the dialdehyde form and Tris buffer homogenizing solution, and also in the running buffer used in GSH-Sepharose affinity chromatography as detailed in Scheme 1. AFB1-dhd was formed by either spontaneous or enzymic hydrolysis ofthe AFB1-8,9-epoxide formed by the quail cytosol from etboxyquin-treated rats Cytosols prepared and fractionated on the Sepharose-GSH column and incubations carried out using previously described methods (Judah et al., 1977; Hayes et al., 1991a Figure 3 ) (19.6 jug of protein) was added where indicated. Incubations (30 min) were terminated by addition of 1 ml of ice-cold methanol.
Samples were clarified by centrifugation (1500 9, 45 min), and the pellets were washed twice with 1 ml of methanol. Radioactivity was determined in combined soluble plus washing fractions and in insoluble fractions (the latter after air-drying and dissolving in 0.1 M KOH) by liquid scintillation counting using acidified Monofluor scintillation solution (National Diagnostics, Aylesbury, Bucks., U.K. utilizing AFB1-dhd in the dialdehyde configuration at physiological pH. The aldehyde reductase activity assayed with pnitrobenzaldehyde present in the fractions eluted from the Protein-PAK Glass SP-8HR column in the final purification step, co-incided with the activity catalysing the formation of the novel metabolite (Figure 4 ). This provides strong evidence that the enzyme is an aldehyde reductase, again consistent with the product being AFB1-dialcohol. Conclusions and possible relevance of AFB1-AR activity
The expression in rat liver of the AFB1-AR activity, at a time of reduced sensitivity to the cytotoxicity of AFB1, is consistent with a role for the enzyme in the resistance phenomenon associated with pre-neoplasia and the response to anti-oxidants such as ethoxyquin. This enzymic mechanism might also have relevance in terms of the development of resistance to other cytotoxic agents the mechanisms of action of which involve metabolism to a reactive aldehyde. It is clearly necessary to examine other systems, in particular human, to determine if this enzyme activity is expressed, and if so in what circumstances, before its potential significance in the carcinogenic process can be evaluated. It would be of great practical importance to establish whether a similar detoxifying system is expressed in the livers of humans consuming diets contaminated with aflatoxins, since such exposure is frequently monitored by assaying serum albuminaflatoxin adducts (Wild et al., 1990 ).
